The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers. The ...

The U.S. Food and Drug Administration has approved three vaccines for RSV — GSK's Arexvy, Moderna's mRESVIA and Pfizer's ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV).

In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy preterm and full-term infants, putting MSD in a position to potentially file ...

The RSV vaccine is now recommended for adults aged 50 to 59 who are at a high risk of severe infection.